Company news
Botanix Pharmaceuticals Limited (ASX:BOT) news
Botanix Pharmaceuticals Limited news releases on 6ix. Latest, Apr 24, 2020: FDA Grants BTX 1801 QIDP Designation Status
Press releases — page 3
FDA Grants BTX 1801 QIDP Designation Status
April 23, 2020
Botanix Provides Update on Development Activities Amended
April 16, 2020
Botanix Provides Update on Development Activities
April 15, 2020
Botanix Announces Top Line BTX 1204 Atopic Dermatitis Data
March 24, 2020
Antimicrobial Platform Update and Launch of BTX 1801 Study
March 12, 2020
Botanix Initiates BTX 1702 Rosacea Study
December 8, 2019
Botanix Announces De-scheduling of Synthetic CBD
November 24, 2019
Botanix Announces BTX 1503 Data and Progression to Phase 3
October 22, 2019
BOT Receives Grant for Synthetic Cannabidiol Analog Program
October 14, 2019
Botanix announces new clinical program to target rosacea
September 15, 2019
Appendix 4E and Annual Report
August 19, 2019
Botanix $40 Million US Lead Placement and Management Update
July 31, 2019
Botanix Antimicrobial Platform Addresses Global Threat
July 14, 2019
BTX 1801 Kills Superbugs Without Resistance World-First
June 19, 2019
Study Confirms Anti-inflammatory and Other Properties of CBD
June 18, 2019
Pause in Trade
June 17, 2019
Dermatology Industry Leader Joins Botanix
May 19, 2019
Botanix Provides Retraction in Presentation
May 16, 2019
Pause In Trading
May 15, 2019
Permetrex Outperforms Other CBD Topical Products
February 25, 2019
Investigators Meeting Completed for BTX 1204 Phase 2 Study
January 24, 2019
Ethics Approval for Phase 2 Atopic Dermatitis Study Received
December 17, 2018
Botanix receives A$4.6m R&D Tax Incentive refund
November 22, 2018
First Patient Treated in BTX 1308 Psoriasis Patient Study
November 6, 2018
Ethics Approval for BTX 1308 Psoriasis Patient Study Secured
September 26, 2018
Botanix BTX 1503 Clinical Trial Update
September 12, 2018
FDA Clears Development Path for BTX 1204
August 29, 2018
Investigators Meeting Completed for BTX 1503 Phase 2 Trial
July 22, 2018
Botanix Joins with UQ to Accelerate Development of BTX 1801
July 18, 2018
Botanix update on development pipeline products
July 1, 2018
First Patients Recruited into BTX 1503 Phase 2 Acne Trial
June 26, 2018
BOT Welcomes First FDA Approval for Cannabidiol Product
June 25, 2018
Botanix Raises A$8m in Oversubscribed Placement
June 20, 2018
Australian Ethics approval for Acne Study
June 12, 2018
BTX 1204 Atopic Dermatitis Study Results Presentation
June 6, 2018
Botanix Announces Successful Atopic Dermatitis Study Results
June 5, 2018
Presentation on Atopic Dermatitis Market
May 22, 2018
FDA Green Light for BTX 1503 Phase 2 Study
May 7, 2018
Appendix 4C - quarterly
April 24, 2018
Enrolment of BTX 1204 Atopic Dermatitis Study Completed
April 9, 2018
Completion of Placement
February 11, 2018
Significantly Oversubscribed A$15m Placement
February 4, 2018
Botanix Announces Successful Acne Study Results
January 28, 2018
Botanix Receives A$1.6m R&D Tax Incentive Refund
January 15, 2018
Botanix Completes Enrolment of BTX 1503 Acne Patient Study
December 17, 2017
New Antibacterial Results Support BTX 1503 Acne Program
December 4, 2017
Botanix Enrols First Patients in Dermatitis Study
November 22, 2017
Botanix Commences BTX 1204 Dermatitis Patient Study
October 30, 2017
FDA Clears Development Path for BTX 1503
October 8, 2017
Botanix Commences BTX 1503 Acne Patient Study
August 20, 2017